Business Description
Arcellx Inc
NAICS : 325412
SIC : 2834
ISIN : US03940C1009
Description
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.19 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -1.52 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 5.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 2.6 | |||||
| 3-Year EPS without NRI Growth Rate | 0.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | -9.26 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.41 | |||||
| 9-Day RSI | 34.79 | |||||
| 14-Day RSI | 34.99 | |||||
| 6-1 Month Momentum % | 105.29 | |||||
| 12-1 Month Momentum % | 74.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.06 | |||||
| Quick Ratio | 6.06 | |||||
| Cash Ratio | 5.94 | |||||
| Days Sales Outstanding | 90.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33.9 | |||||
| Shareholder Yield % | -4.98 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -81.47 | |||||
| Net Margin % | -63.78 | |||||
| FCF Margin % | 168.73 | |||||
| ROE % | -22.64 | |||||
| ROA % | -11.73 | |||||
| ROIC % | -44.44 | |||||
| ROC (Joel Greenblatt) % | -121.49 | |||||
| ROCE % | -14.21 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 23.15 | |||||
| PB Ratio | 5.69 | |||||
| Price-to-Tangible-Book | 5.69 | |||||
| Price-to-Free-Cash-Flow | 13.37 | |||||
| Price-to-Operating-Cash-Flow | 12 | |||||
| EV-to-EBIT | -34.7 | |||||
| EV-to-Forward-EBIT | -20.76 | |||||
| EV-to-EBITDA | -35.81 | |||||
| EV-to-Forward-EBITDA | -17.13 | |||||
| EV-to-Revenue | 20.82 | |||||
| EV-to-Forward-Revenue | 34.79 | |||||
| EV-to-FCF | 12.34 | |||||
| Price-to-Net-Current-Asset-Value | 7.34 | |||||
| Price-to-Net-Cash | 7.62 | |||||
| Earnings Yield (Greenblatt) % | -2.88 | |||||
| FCF Yield % | 6.61 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers